Jessica Ochalek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7536959/publications.pdf

Version: 2024-02-01

17	559	933447 10	888059 17
papers	citations	h-index	g-index

17	17	17	805
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries. Health Policy and Planning, 2022, 37, 45-54.	2.7	8
2	Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates. Pharmacoeconomics, 2022, 40, 31-43.	3.3	16
3	Supporting a review of the benefits package of the National Health Insurance Scheme in Ghana. Cost Effectiveness and Resource Allocation, 2022, 20, .	1.5	5
4	Valuing health outcomes: developing better defaults based on health opportunity costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 729-736.	1.4	16
5	Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment. Applied Health Economics and Health Policy, 2021, , 1.	2.1	10
6	Concomitant health benefits package design and research prioritisation: development of a new approach and an application to Malawi. BMJ Global Health, 2021, 6, e007047.	4.7	1
7	Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. BMJ Global Health, 2020, 5, e003006.	4.7	14
8	Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach. Pharmacoeconomics, 2020, 38, 1319-1331.	3.3	48
9	Squaring the cube: Towards an operational model of optimal universal health coverage. Journal of Health Economics, 2020, 70, 102282.	2.7	6
10	Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. Clinical Therapeutics, 2020, 42, 44-59.e2.	2.5	16
11	What next after GDP-based cost-effectiveness thresholds?. Gates Open Research, 2020, 4, 176.	1.1	36
12	Accounting for Timing when Assessing Health-Related Policies. Journal of Benefit-Cost Analysis, 2019, 10, 73-105.	1.2	17
13	A one stop shop for cost-effectiveness evidence? Recommendations for improving Disease Control Priorities. Cost Effectiveness and Resource Allocation, 2019, 17, 7.	1.5	9
14	Cost-Effectiveness Thresholds: the Past, the Present and the Future. Pharmacoeconomics, 2018, 36, 509-522.	3.3	124
15	Supporting the development of a health benefits package in Malawi. BMJ Global Health, 2018, 3, e000607.	4.7	42
16	Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Global Health, 2018, 3, e000964.	4.7	181
17	Causal effects of HIV on employment status in low-income settings. Economics and Human Biology, 2017, 27, 248-260.	1.7	10